Aimovig (erenumab) is a once-monthly self-injected antibody that blocks the CGRP receptor to prevent migraine, and it is a refrigerated biological that an importer buys as the originator in 70 mg or 140 mg pens or syringes.

We do not publish prices. The landed cost of erenumab depends on the strength (70 mg or 140 mg), the device (pen, autoinjector or syringe), the quantity, the registration route in your destination, the cold-chain lane and the Incoterms. Refrigerated freight is a real cost line for a 2 to 8 °C biological with a 7-day room-temperature allowance. Because each device holds one 1 mL dose, the number of devices drives freight volume. M Care Exports quotes per destination once you send the strength, device, volume and country.

Both are 1 mL single-dose devices. The FDA label recommends 70 mg subcutaneously once monthly, and says some patients may benefit from 140 mg once monthly. The EU SmPC gives 70 mg every 4 weeks, with 140 mg for some patients, and allows a 140 mg dose as one 140 mg injection or two 70 mg injections. Treatment is for adults. The SmPC says to consider stopping if there is no response after 3 months. They are separate purchasing lines, so tell us which strength each clinic uses.

Both a device and a syringe exist, and the device name differs by market. The FDA label lists single-dose prefilled SureClick autoinjectors and single-dose prefilled glass syringes, in 70 mg and 140 mg, each supplied as a pack of one. The EU SmPC lists pre-filled pens and pre-filled syringes in both strengths, in packs of one, plus a multipack of three pens, and notes that not all pack sizes may be marketed. Tell us which device your registration or formulary names, and we quote that presentation.

On label facts only. The EMA page for Aimovig describes erenumab as attaching to the receptor for CGRP. The EMA pages for Emgality (galcanezumab, Eli Lilly Nederland B.V.) and Ajovy (fremanezumab, Teva GmbH) describe antibodies designed to attach to CGRP, so the stated target differs. Aimovig is given once monthly in 70 mg, with 140 mg for some patients. The EMA page for Ajovy gives 225 mg monthly or 675 mg every three months. The Emgality page gives a starting dose of two injections, then one a month. We do not recommend one product over another; the choice is clinical and formulary-led.

In the US, Drugs@FDA lists Aimovig under BLA 761077 held by Amgen Inc. The EMA page for Aimovig names Novartis Europharm Limited as holder and mentions no biosimilar. We found no erenumab biosimilar in the FDA and EMA sources we checked. We have not confirmed an Indian registration from a CDSCO approval list, so we make no claim for India. Other CGRP antibodies are different molecules, not generics of erenumab, and the choice between them is clinical.

Constipation is the one to plan for. The EU SmPC calls it a common adverse reaction, usually mild or moderate, with onset often after the first dose and resolution within three months in most cases. Serious complications, including hospitalisation and surgery, have been reported in the post-marketing setting. The EU SmPC warns of serious hypersensitivity, which can occur within minutes or more than a week after treatment, and the FDA label also lists hypersensitivity reactions. The FDA label also warns of new or worsening hypertension and Raynaud's phenomenon. The FDA label contraindicates serious hypersensitivity to erenumab or any excipient, and the EU SmPC contraindicates hypersensitivity to erenumab or any excipient.